Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
06 Outubro 2022 - 9:00AM
Business Wire
Presenters include leading neuro-oncologists
Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A.
Nagpal of Stanford University
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces an hour-long
webinar to be held October 14 at 1 p.m. Eastern time featuring case
studies presented by leading neuro-oncologists who have used the
company’s CNSide assay in the management of patients with confirmed
or suspected central nervous system metastasis. The webinar will
feature key opinion leaders Priya U. Kumthekar, MD of Northwestern
University and Seema A. Nagpal, MD of Stanford University.
“We appreciate Drs. Kumthekar and Nagpal’s willingness to share
their real-world clinical experience with CNSide, in managing
patients with a time-sensitive, life-threatening complication of
cancer,” said Michael Dugan, MD, Biocept’s Senior Vice President,
Chief Medical Officer and Medical Director. “CNSide provides an
enhanced method of cell capture with digital imaging for the
quantitative evaluation of tumor cells recovered from cerebral
spinal fluid (CSF). This provides a more accurate method of
assessing the intracranial response to
treatment than more subjective methods currently used to
evaluate metastatic cancers involving the central nervous system.
Additionally, CNSide can be used to identify biomarkers associated
with tumor progression and metastasis to better inform physician
treatment decisions and patient care plans, while providing tumor
cell counts that can be used by them to more quickly assess both
treatment response and disease progression or resistance to
treatment.”
“Our goals are to position Biocept as the leader in the emerging
category of neurological tumor diagnostics, and to become the
provider of choice for biopharma companies seeking to develop
therapies to treat cancer that has metastasized to the central
nervous system,” said Sam Riccitelli, Biocept’s Chairman and
interim CEO. “Our customer base has consistently grown since
CNSide’s early access commercial launch in early 2020. More than
100 physicians including physicians from more than one-third of the
elite 64 National Cancer Institute-designated cancer centers have
used our product. We estimate the annual market opportunity for
CNSide for our initial applications at $1.2 billion in the U.S. and
$2 billion globally.”
Webinar Details
Date: Friday, October 14 Time: 1:00 p.m. Eastern
time (10:00 a.m. Pacific time) Registration: Participants
can pre-register or register at webinar start time here
The webinar will be available live and archived at
www.biocept.com.
About the Speakers
Priya U. Kumthekar, MD is a United Counsel for Neurologic
Subspecialties (UCNS)-certified neuro-oncologist from Northwestern
University and is serving as the principal investigator for
Biocept’s FORESEE clinical study. She is dedicated to patient care
and moving the study of brain tumors forward primarily through her
leadership on clinical trials. Dr. Kumthekar serves in leadership
roles with the National Clinical Trials Network, particularly with
the Alliance for Clinical Trials, and was named as the Alliance’s
national Executive Officer of Neuro-Oncology in 2016. In this role,
she oversees the conception and development of clinical trials from
early phase through registration studies. Dr. Kumthekar is board
certified in neurology and is a member of the American Board of
Psychiatry and Neurology. She received her medical degree from
Northeastern Ohio University. She previously was Chief Resident at
Northwestern University, McGaw Medical Center and has led numerous
trials involving primary and secondary brain tumors.
Seema A. Nagpal, MD is a board-certified neuro-oncologist
and has served as Clinical Associate Professor at Stanford
University since 2012. She treats patients with primary brain
tumors and metastatic disease to the brain and nervous system. Her
research concentrates on clinical trials for patients with
late-stage central nervous system cancer and she has a special
interest in leptomeningeal disease, a devastating complication of
lung and breast cancers. In collaboration with Stanford scientists,
including breast and lung oncologists, Dr Nagpal’s work is focused
on more sensitive disease detection and the improvement of patient
outcomes. She previously was a neuro-oncology fellow at Stanford
hospitals and clinics, and a neurology resident at the University
of California San Francisco. She received her medical degree from
the University of Pennsylvania.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
establish our CSF assay as the new standard of care for the
diagnosis of patients with suspected cancer metastasis to the CNS
under National Comprehensive Cancer Network guidelines and our
ability to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221006005286/en/
Investor and Media Contact
LHA Investor Relations Jody Cain Jcain@lhai.com, (310)
691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024